BioinvestGPT

BioinvestGPT ApS · Research use only

NCT02768363 (CAN2409 in newly diagnosed prostate cancer): BVCT ex-ante prediction vs. reported outcome

On 6 Aug 2024, BioinvestGPT's BVCT predicted technical failure and commercial failure for this trial. The 11 Dec 2024 readout is classified on the dashboard as True Negative (TN), a correct prediction. Recorded clinical-benefit conclusion: statistically insignificant and commercially insufficient.

Clinical Trial

NCTID
NCT02768363
Acronym
ULYSSES
Drug Name
CAN2409
Drug MoA
AAV-mediated intratumoral delivery of HSV-TK as an oncolytic viral therapy
Drug Modality
oncolytic viral gene therapy
Drug Class
First-In-Class
Therapeutic Area
Neoplasms
Indication
newly diagnosed prostate cancer
Human Patients
187
Sponsor
Candel Therapeutics
Phase
Phase 2

Prediction of , index 420

Prospective Prediction
Prediction Index
420
Prediction Date
Commercial Prediction
FAILURE (commercially insufficient clinical benefit in OS)
Technical Prediction
FAILURE (statistically insignificant clinical benefit in PFS)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
127 days in advance
Readout Data Interpretation
CAN2409 failed achieved statistically significance in DFS
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically insignificant and commercially insufficient
Prediction Classification
True Negative (TN)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
A Randomized Controlled Trial Of AdV-tk + Valacyclovir Administered During Active Surveillance For Newly Diagnosed Prostate Cancer
Phase
Phase 2
Status
Active not recruiting
Enrollment
187
Lead sponsor
Candel Therapeutics, Inc.
Conditions
Prostate Cancer
Interventions
BIOLOGICAL: aglatimagene besadenovec; BIOLOGICAL: placebo; DRUG: valacyclovir
Design
Randomized · Parallel · Quadruple
Primary purpose
Treatment
Start
2016-05
Primary completion
2024-11
Completion
2026-12
Primary outcomes
  • Progression-free survival (PFS) (Baseline to study completion, approximately 5 years)

NCT02768363 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials